Thyrotoxicosis and hypercalcaemia: response to antithyroid drugs and salmon calcitonin.
Four patients with thyrotoxicosis, hypercalcaemia and metabolic bone disease are described. One of them had a 'hot nodule', T3 toxicosis and a parathyroid tumour and another had thin bones, subperiosteal cortical bone erosions and complete dysphagia. Hypercalcaemia persisted during treatment with antithyroid drugs in two patients, both of whom had hyperparathyroidism. The administration of salmon calcitonin to these two patients before starting antithyroid treatment produced an immediate and sustained fall in serum calcium and urinary hydroxyproline levels. Calcitonin administration should be of value in the early management of hypercalcaemic patients.
D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D013956:Antithyroid Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006980:Hyperthyroidism / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D012474:Salmon; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood; D014508:Urea / Q000097:blood
D013956:Antithyroid Agents; D010710:Phosphates; D014284:Triiodothyronine; D014508:Urea; D002116:Calcitonin; D000469:Alkaline Phosphatase; D013974:Thyroxine; D002118:Calcium